April 13, 2021 08:47 AM EDTUpdated April 27, 09:16 AM

Covid-19 roundup: Citing a lack of need, Gilead cuts remdesivir study; Novavax vaccine production slowed due to supply shortages

Josh Sullivan

Nicole DeFeudis

Editor

Gilead is halting its remdesivir study in high-risk, non-hospitalized Covid-19 patients after a decision that the study no longer addresses an unmet need, a statement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Citing a lack of need, Gilead cuts remdesivir study; Novavax vaccine production slowed due to supply shortages

Josh Sullivan

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Covid-19 roundup: Cit­ing a lack of need, Gilead cuts remde­sivir study; No­vavax vac­cine pro­duc­tion slowed due to sup­ply short­ages

Editor

Sign up to read this article for free.

more like this

Covid-19 roundup: Citing a lack of need, Gilead cuts remdesivir study; Novavax vaccine production slowed due to supply shortages